Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alonso Villasmil-Ocando"'
Autor:
Kyle Pedro, Alonso Villasmil Ocando, Benjamin Primack, Meghan Langley, Theresa Ross, Jeremy Tchaicha, Michelle Ols, Jan ter Meulen, Violet Young, Gauri Kulkarni, Arman Aksoy, Rachel A Burga
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7fe68b97f73249be9b4b5a446cd02a74
Autor:
Subha Dahal, Kiera Clayton, Terek Been, Raphaële Fernet-Brochu, Alonso Villasmil Ocando, Ahalya Balachandran, Mikaël Poirier, Rebecca Kaddis Maldonado, Lulzim Shkreta, Kayluz Frias Boligan, Furkan Guvenc, Fariha Rahman, Donald Branch, Brendan Bell, Benoit Chabot, Scott D. Gray-Owen, Leslie J. Parent, Alan Cochrane
Publikováno v:
Retrovirology, Vol 19, Iss 1, Pp 1-25 (2022)
Plain Language Summary Identifying cellular factors that regulate HIV-1 RNA processing provides important insights into novel strategies to control this infection. Different members of the SR kinase family have distinct roles in regulating virus expr
Externí odkaz:
https://doaj.org/article/f6c59f5364bf49b0a2fb808840fdf7ed
Autor:
Gabriel Helmlinger, Rachel Burga, Stanley Tam, Mithun Khattar, Scott Lajoie, Kyle Pedro, Colleen Foley, Alonso Villasmil Ocando, Jack Tremblay, Benjamin Primack, Meghan Langley, Dan Thornton, Emily Brideau, Theresa Ross, Gwen Wilmes, Sunandan Saha, Jeremy Tchaicha, Dhruv Sethi, Michelle Ols, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/96bcf551331a468aa219481d0e648459
Autor:
Rachel Burga, Zheng Ao, Arman Aksoy, Scott Lajoie, Kyle Pedro, Jack Tremblay, Gauri Kulkarni, Alonso Villasmil Ocando, Benjamin Primack, Meghan Langley, Theresa Ross, Jeremy Tchaicha, Michelle Ols, Jan ter Meulen, Mithun Khattar
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f60435577d576c1a0d4dce195a3a472
https://doi.org/10.1136/jitc-2022-sitc2022.0390
https://doi.org/10.1136/jitc-2022-sitc2022.0390
Autor:
Kyle D. Pedro, Rachel Burga, Alonso Villasmil Ocando, Meghan Langley, Gauri Kulkarni, Zheng Ao, Benjamin Primack, Theresa Ross, Violet Young, Jeremy Tchaicha, Michelle Ols, Jan Ter Meulen
Publikováno v:
Cancer Research. 83:LB096-LB096
Tumor infiltrating lymphocyte (TIL) therapy has shown promising results in the treatment of metastatic melanoma. However, TIL therapy has conventionally required co-administration of IL2, which is associated with toxicity in patients. We previously s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74e7ca0273a2ab10b9dcc342c937d457
https://doi.org/10.1158/1538-7445.am2023-lb096
https://doi.org/10.1158/1538-7445.am2023-lb096
Autor:
Sunandan Saha, Rachel A. Burga, Meghan Langley, Michelle Ols, Jack Tremblay, Stanley Tam, Jeremy Hatem Tchaicha, Benjamin Primack, Colleen Foley, Gabriel Helmlinger, Theresa Ross, Sethi Dhruv Kam, Emily Brideau, Shyam Subramanian, Alonso Villasmil Ocando, Kyle Pedro, Mithun Khattar, Scott Lajoie, Gary Vanasse, Dan Thornton, Jan ter Meulen, Gwen Wilmes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated tremendous promise in clinical trials for patients with solid or metastatic tumors.1 However, current TIL therapy requires systemic administration of IL-2 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815d303531e342b20426e223fe2accb8
https://doaj.org/article/96bcf551331a468aa219481d0e648459
https://doaj.org/article/96bcf551331a468aa219481d0e648459
Autor:
Jeremy H. Tchaicha, Scott Lajoie, Rachel Burga, Theresa Ross, Benjamin Primack, Meghan Langley, Violet Young, Alonso Villasmil Ocando, Kyle Pedro, Jack Tremblay, Gauri Kulkarni, Mithun Khattar, Dhruv Sethi, Michelle Ols, Gabriel Helmlinger, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Publikováno v:
Cancer Research. 82:LB212-LB212
Standard tumor-infiltrating lymphocyte (TIL) therapy requires IL-2 administration to support TIL expansion and survival, but this cytokine is associated with T cell exhaustion and can result in severe toxicities that limit patient eligibility (1). To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f0d1de8de6cd30910cbaaa8f00979f7
https://doi.org/10.1158/1538-7445.am2022-lb212
https://doi.org/10.1158/1538-7445.am2022-lb212
Autor:
Bruce D. Walker, Hidde L. Ploegh, Geetha H. Mylvaganam, Alonso Villasmil-Ocando, Heather Stuart, Kiera L. Clayton, Marcela V. Maus, Mohammad Rashidian
Publikováno v:
Cell Host Microbe
Summary Natural killer (NK) cells are innate cytolytic effectors that target HIV-infected CD4+ T cells. In conjunction with antibodies recognizing the HIV envelope, NK cells also eliminate HIV-infected targets through antibody-dependent cellular cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c130e4da009c13692542f4d7281d36dc
https://doi.org/10.1016/j.chom.2021.01.006
https://doi.org/10.1016/j.chom.2021.01.006